Updated on 4 September 2013
"There are no regulations guiding how a drug maker should promote a new product to hospitals and doctors. The doctors learned their knowledge at medical schools years ago, and they do not know about the latest developments in pharmacology," he explained to the media.
He has suggested that establishing an industry regulation that guides the drug purchases of hospitals, enabling an open channel through which drug companies can pitch their products are workable solutions.
Mr Yu Mingde, chairman, China Pharmaceutical Enterprises Association, believes that the solution to the issue of corruption lies in reform of the public hospital system to ensure the incomes of doctors.
"Despite the ongoing medical reforms, many hospitals still rely on pharmaceutical sales to maintain their operations, which is a major reason for bribery from pharmaceutical companies. The problem can only be solved through reform of funding sources for public hospitals, and enabling them to open their operations to the market," he said.